These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

473 related articles for article (PubMed ID: 22336699)

  • 1. Botulinum toxins in the treatment of primary focal dystonias.
    Truong D
    J Neurol Sci; 2012 May; 316(1-2):9-14. PubMed ID: 22336699
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Botulinum neurotoxins for the treatment of focal dystonias: Review of rating tools used in clinical trials.
    Del Sorbo F; Albanese A
    Toxicon; 2015 Dec; 107(Pt A):89-97. PubMed ID: 26365917
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The broadening application of chemodenervation in X-linked dystonia-parkinsonism (Part II): an open-label experience with botulinum toxin-A (Dysport®) injections for oromandibular, lingual, and truncal-axial dystonias.
    Rosales RL; Ng AR; Santos MM; Fernandez HH
    Int J Neurosci; 2011; 121 Suppl 1():44-56. PubMed ID: 21348790
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evidence-based review and assessment of botulinum neurotoxin for the treatment of movement disorders.
    Hallett M; Albanese A; Dressler D; Segal KR; Simpson DM; Truong D; Jankovic J
    Toxicon; 2013 Jun; 67():94-114. PubMed ID: 23380701
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Treatment of focal dystonia with botulinum toxin A].
    Sojer M; Wissel J; Müller J; Poewe W
    Wien Klin Wochenschr; 2001; 113 Suppl 4():6-10. PubMed ID: 15506045
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of Blepharospasm and Oromandibular Dystonia with Botulinum Toxins.
    Hassell TJW; Charles D
    Toxins (Basel); 2020 Apr; 12(4):. PubMed ID: 32331272
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The broadening application of chemodenervation in X-linked dystonia-parkinsonism (Part I): muscle afferent block versus botulinum toxin-A in cervical and limb dystonias.
    Rosales RL; Santos MM; Ng AR; Teleg R; Dantes M; Lee LV; Fernandez HH
    Int J Neurosci; 2011; 121 Suppl 1():35-43. PubMed ID: 21244305
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Update on the Use of Botulinum Toxin Therapy for Focal and Task-Specific Dystonias.
    Lungu C; Ahmad OF
    Semin Neurol; 2016 Feb; 36(1):41-6. PubMed ID: 26866495
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Use of botulinum neurotoxin therapy].
    Mukai Y; Kaji R
    Brain Nerve; 2011 Jul; 63(7):775-84. PubMed ID: 21747148
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Botulinum toxin treatment of occupational and focal hand dystonia.
    Karp BI
    Mov Disord; 2004 Mar; 19 Suppl 8():S116-9. PubMed ID: 15027063
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Craniocervical dystonia: clinical and pathophysiological features.
    Colosimo C; Suppa A; Fabbrini G; Bologna M; Berardelli A
    Eur J Neurol; 2010 Jul; 17 Suppl 1():15-21. PubMed ID: 20590803
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of long-term botulinum toxin treatment in craniocervical dystonia: a systematic review.
    Colosimo C; Tiple D; Berardelli A
    Neurotox Res; 2012 Nov; 22(4):265-73. PubMed ID: 22359151
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Long-term evolution of the doses of Botulinum toxin used in laryngeal and cervical dystonias].
    García-Torres MA; Echeverría-Urabayen A; Contreras A; Carnal-Martín P; García-Ruiz Espiga PJ
    Rev Neurol; 2005 Nov 1-15; 41(9):525-6. PubMed ID: 16254858
    [TBL] [Abstract][Full Text] [Related]  

  • 14. EFNS guidelines on diagnosis and treatment of primary dystonias.
    Albanese A; Asmus F; Bhatia KP; Elia AE; Elibol B; Filippini G; Gasser T; Krauss JK; Nardocci N; Newton A; Valls-Solé J
    Eur J Neurol; 2011 Jan; 18(1):5-18. PubMed ID: 20482602
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Disease-oriented approach to botulinum toxin use.
    Jankovic J
    Toxicon; 2009 Oct; 54(5):614-23. PubMed ID: 19073203
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New trends in the science of botulinum toxin-A as applied in dystonia.
    Pickett A; Rosales RL
    Int J Neurosci; 2011; 121 Suppl 1():22-34. PubMed ID: 21244295
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Botulinum toxin in the treatment of dystonias--a hospital based study.
    Gupta M; Singh G; Khwaja G
    J Assoc Physicians India; 2003 May; 51():447-53. PubMed ID: 12974424
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Health related quality of life is improved by botulinum neurotoxin type A in long term treated patients with focal dystonia.
    Hilker R; Schischniaschvili M; Ghaemi M; Jacobs A; Rudolf J
    J Neurol Neurosurg Psychiatry; 2001 Aug; 71(2):193-9. PubMed ID: 11459891
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Botulinum toxin type B in the management of dystonia non-responsive to botulinum toxin type A].
    Cardoso F
    Arq Neuropsiquiatr; 2003 Sep; 61(3A):607-10. PubMed ID: 14513166
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adult-onset focal dystonias: presentation and treatment options.
    Esper GJ; Charles PD; Davis TL; Robertson D
    Tenn Med; 1997 Jan; 90(1):18-20. PubMed ID: 8997156
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.